Introduction
============

The incidence of renal cancer ranks eighth among all malignant diseases worldwide ([@b1-ol-0-0-5349]), while its mortality rate ranks sixth ([@b2-ol-0-0-5349]). Clear cell carcinoma is the dominant pathological type of renal cancer ([@b1-ol-0-0-5349]). Early renal carcinoma (RC) has atypical clinical symptoms and signs, which are easily overlooked. This, coupled with the lack of specific tumor markers, makes early diagnosis of RC remarkably difficult ([@b3-ol-0-0-5349]). Furthermore, it is easy for RC to progress into a late stage, since transfer or invasion of real cancer cells into the surrounding organs occurs at an early stage, as the kidney does not have a serous layer and is located adjacent to the trachea, aorta and other important organs. Clinically, \>1/2 of patients with RC had missed the opportunity to remove the tumor at diagnosis, which is a challenge for the clinicians ([@b3-ol-0-0-5349]). At present, the treatment of RC that has been widely used is the combined strategy of surgical excision, radiotherapy and chemotherapy, but its efficiency is still unsatisfactory, since the 5-year survival rate following surgery is only 20--40% ([@b4-ol-0-0-5349],[@b5-ol-0-0-5349]).

Apoptosis is not only a normal cell cycle process, but it is also vital for homeostasis, since it can remove excessive damaged and aging mutant cells ([@b6-ol-0-0-5349]). Apoptosis disorders are involved in the pathogenesis of a variety of malignant tumors, and are considered to be the key reason for the occurrence and development of tumors, being closely associated with tumor drug resistance ([@b3-ol-0-0-5349]). Inhibition of apoptosis leads to the accumulation of mutations in the cell, which initiates differentiation ([@b7-ol-0-0-5349]). Malignant cells do not die if insufficient apoptosis occurs ([@b8-ol-0-0-5349]).

The members of the family of inhibitor of apoptosis proteins (IAPs), which contains eight members, are the key regulators of cytokinesis, apoptosis and signal transduction, and have been demonstrated to be closely associated with oncogenesis ([@b9-ol-0-0-5349]). Apollon, namely baculoviral IAP repeat containing 6 (BIRC6), is a membrane-associated protein that localizes to the Golgi compartment and the vesicular system, and is the largest member of the IAP family ([@b9-ol-0-0-5349]). It inhibits apoptosis by binding to cysteine aspartate-specific proteases (caspases) directly. Its anti-apoptotic function is much stronger than that of the proteins of the B-cell lymphoma-2 family, mainly through the function of Smac, high temperature requirement A protein serine peptidase 2 and caspase ([@b10-ol-0-0-5349],[@b11-ol-0-0-5349]). Increasing evidence has shown that upregulation of Apollon may be important in tumor generation ([@b12-ol-0-0-5349]--[@b16-ol-0-0-5349]). However, the association between RC and Apollon is unclear.

In the present study, Apollon expression was detected by immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in RC tissues, adjacent non-cancerous tissues and normal tissues respectively, in order to analyze the association between Apollon expression and the clinicopathological features of RC, and to highlight the link between Apollon expression and the occurrence, development and prognosis of RC.

Materials and methods
=====================

### Patients and specimens

The patients enrolled in the present study were recruited from the Third Affiliated Hospital of Southern Medical University (Guangzhou, China) from February 2010 till February 2014. The patients were diagnosed as RC by \>2 pathologists. Specimens, including 50 cases of cancer tissue, 42 cases of adjacent non-cancerous tissue and 30 cases of paired normal tissue, were obtained by intraoperative radical renalectomy. The patients included 48 males and 2 females, who were \<75 years old. All patients were first-diagnosed cases, without chemotherapy, radiotherapy or other treatments prior to being sampled, and their clinical and pathological data were complete and reliable. The present study was approved by the Third Affiliated Hospital of Southern Medical University. The usage of information and the collection of specimens was conducted once informed consent from the patients or their families was obtained.

### Reagents and equipment

Anti-Apollon antibody was purchased from Abcam (Cambridge, UK) (ab84429). The PowerVision two-step immunohistochemistry kit was purchased from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd. (Beijing, China) (PV-6001). TRIzol, for total RNA extraction, was purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA) (15596--026). The RT kit was purchased from Promega Corporation (Madison, WI, USA) (A5001). The RT-qPCR kit was purchased from Promega Corporation (A6001). Paraffin-embedding equipment, paraffin-slicing equipment and the automatic upright microscope system (DM5000 B) were purchased from Leica Microsystems GmbH (Wetzlar, Germany). The 400W ultraviolet imaging system was purchased from Kodak (Rochester, NY, USA). The PCR equipment (ABI PRISM 7500 Sequence Detection System) was purchased from Applied Biosystems (Thermo Fisher Scientific, Inc.). The Total Protein Extraction kit, polyvinylidene difluoride membranes and Beyo-ECL Plus Detection System were purchased from Beyotime Institute of Biotechnology (Haimen, China).

### Immunohistochemistry

The rapid PowerVision two-step staining method was used with the following specifications: Paraffin slices were obtained with a thickness of 5 µm, which were next incubated at 65°C for 60 min, followed by dewaxing, hydration and high-temperature antigen retrieval in a microwave by incubation in a 0.1 M citrate solution (pH 6.0) for 10 min. Next, the slides were incubated with 3% H~2~O~2~ at room temperature for 20 min, followed by incubation with goat serum (ab7481; Abcam) at room temperature for 20 min and incubation with anti-Apollon antibody (1:400; ab19609; Abcam) at 4°C overnight. The slides were heated up the following day prior to being incubated with an anti-rabbit antibody at room temperature for 20 min. Subsequently, the slides were subjected to 3,3′-diaminobenzidine and hematoxylin staining, prior to being mounted for light microscopic examination. Immunohistochemical staining was scored independently by two pathologists without knowledge of the patients\' characteristics. Any discrepancy was solved by consensus review. The score of immunoreactivity was performed by calculating the extent and intensity of positive staining of cells in a semi-quantitative manner. Score interpretation was performed as described previously ([@b17-ol-0-0-5349]). The standards for evaluation included the following: Positive staining intensity (0, negative; 1, weak positive; 2, moderate positive; and 3, strong positive) and proportion of positive areas (0, 0%; 1, 1--30%; 2, 30--70%; and 4, 70--100%). The final score was obtained by multiplication of the aforementioned two scores, with 0 regarded as negative, 1--2 regarded as weak positive, 3--4 regarded as moderate positive and ≥5 regarded as strong positive. The negative and weak-moderate positive results were considered as low expression of Apollon, while the strong positive results were considered as Apollon overexpression. RC patients were divided into a low-expression group or a high-expression group, based on their final score, which was considered as high expression if its value was \>5.

### Western blotting

Tissues were lysed with the Total Protein Extraction kit (Beyotime Institute of Biotechnology), and the protein lysates were resolved on 12% SDS-PAGE prior to being transferred to polyvinylidene difluoride membranes (IPFL00010; EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% milk and then incubated for 2 h with primary antibodies against Apollon (ab19609; Abcam) and GAPDH (ab8245; Abcam) at 37°C. The membranes were washed with PBS containing Tween 20 and then incubated with the secondary antibody (ab131366; Abcam). The Beyo-ECL Plus Detection System (Beyotime Institute of Biotechnology) was employed to visualize the bands. The Apollon protein expression levels were quantified by Image Lab Software 5.1 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and represented as the densitometric ratio of the targeted protein to GAPDH.

### RT-qPCR

Total RNA was extracted from 1 mg renal tissue using TRIzol (Invitrogen (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. Upon treatment with DNA-free DNase (Ambion; Thermo Fisher Scientific, Inc.) to remove the chromosomal DNA, complementary (c)DNA was synthesized using an RT kit (Promega Corporation) and stored at −20°C until use. The messenger RNA (mRNA) expression levels of Apollon and β-actin were determined by RT-qPCR using the ABI PRISM 7500 Sequence Detection System. The primer sequences (sense/anti-sense) were: Apollon, 5′-TGACAGGGCATACATCACAG-3′/5′-GCAACAATCTCCCACTGAAG-3′ and β-actin, 5′-GCACCACACCTTCTACAATGAG-3′/5′-GATAGCACAGCCTGGATAGCA-3′. The mRNA expression levels of the target genes were normalized to the β-actin signal, which served as a housekeeping gene. All the reactions were performed in triplicate using 20-µl samples containing 50 ng cDNA. The reaction protocol involved heating for 10 min at 95°C, followed by 40 cycles of amplification (15 sec at 95°C and 1 min at 60°C). The data were analyzed using the ABI PRISM 7500 Sequence Detection software version 1.2 (Applied Biosystems; Thermo Fisher Scientific, Inc.). The levels of Apollon expression in unknown samples were calculated as a ratio of Apollon to β-actin. Determinations were performed three times for each sample.

### Statistical analysis

The patients were categorized into two groups according to their level of Apollon expression (high Apollon expression group and low Apollon expression group). The differences in Apollon expression with respect to the clinical factors at diagnosis, including gender, age, alcohol consumption history, tumor size, histological grade, T-stage, N-stage and tumor-node-metastasis (TNM)-stage, were analyzed. The expression levels are presented as median values. The quantitative data were compared using one-way analysis of variance and unpaired t test, while the qualitative data were compared using Pearson\'s χ^2^ test. Statistical analyses were conduced with SPSS 19.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients

In total, 50 patients (males, 48; females, 2) were enrolled in the study. Their mean age was 58.6 years (range, 42--74 years). According to the 7th edition of the International Union Against Cancer\'s renal cancer staging manual (2009 edition), the enrolled patients were classified as follows: 4 cases of stage I, 20 cases of stage II and 26 cases of stage III ([@b12-ol-0-0-5349]).

### Increased Apollon protein and mRNA expression in RC tissues

#### Immunohistochemical staining

Apollon protein was detected by immunohistochemical staining ([Fig. 1](#f1-ol-0-0-5349){ref-type="fig"}). Apollon protein was expressed in RC tissues, adjacent non-cancerous tissues and normal renal tissues. Apollon expression was detected mainly in the cytoplasm of the carcinoma cells and in the cytoplasm of the clear cell carcinoma cells or underlying basal cells of the adjacent or normal tissues.

The positive reactants of Apollon were yellow or brown substances that mainly existed in the cytoplasm ([Fig. 1](#f1-ol-0-0-5349){ref-type="fig"}). According to the aforementioned standards, the expression rate of Apollon was 56% (28/50) in the tumor tissue, while it was 5% (2/42) in the adjacent non-cancerous tissue and 0% (0/30) in the normal renal mucosa epithelial tissue. This difference was statistically significant (P\<0.001) ([Table I](#tI-ol-0-0-5349){ref-type="table"}).

#### RT-qPCR and western blotting

The mRNA expression of Apollon in each group was normalized against the endogenous mRNA expression of the housekeeping gene β-actin. The relative expression of Apollon mRNA was described as 2^−ΔΔCq^ ([@b18-ol-0-0-5349]). Apollon expression in RC tissues was significantly higher than that in adjacent non-cancerous tissues and normal renal tissues (P=0.012) ([Fig. 2A](#f2-ol-0-0-5349){ref-type="fig"}). Western blotting analysis also revealed that Apollon protein expression in RC tissues was significantly higher than that in adjacent non-cancerous tissues and normal tissues ([Fig. 2B](#f2-ol-0-0-5349){ref-type="fig"}).

#### Apollon expression and clinicopathological variables

The association between Apollon high expression (score ≥5) and various clinicopathological features was analyzed as aforementioned ([Table II](#tII-ol-0-0-5349){ref-type="table"}). There was no correlation between Apollon overexpression and age (P=0.823), gender (P=0.201), histological grade (P=0.156), tumor size (P=0.749) or alcohol consumption history (P=0.976). Significant associations were observed between Apollon overexpression and nodal involvement (P=0.007), T-stage (P=0.006) and TNM-stage (P=0.035) ([Table II](#tII-ol-0-0-5349){ref-type="table"}).

#### Survival analysis

In total, 80% (40 of 50) of the patients were followed up successfully (the remaining 10 patients could not be contacted). To evaluate the effect of Apollon expression on survival, Kaplan-Meier analysis and log-rank test were used. The results indicated that high level of Apollon expression was correlated with short overall survival (OS) (P=0.017) ([Fig. 3](#f3-ol-0-0-5349){ref-type="fig"}).

Univariate analysis revealed that Apollon expression, T-stage, TNM-stage and tumor size were associated with OS, while tumor differentiation, age or alcohol consumption history had no prognostic significance for OS ([Table III](#tIII-ol-0-0-5349){ref-type="table"}).

Discussion
==========

Apollon is the largest member of the IAP family ([@b19-ol-0-0-5349]), and it was identified by Chen *et al* in 1999 ([@b19-ol-0-0-5349]). The Apollon gene locates on 2p21-22, and encodes a markedly large protein (530 kDa) that contains a single BIR domain and an ubiquitin-conjugating enzyme domain. Apollon is abundant in brain, placenta, testis, lymphatic cells and secretory organs ([@b19-ol-0-0-5349]). Different studies have reported that Apollon is a dual regulator of cell proliferation and cell death, with multiple functions due to its different functional domains and diverse binding patterns ([@b9-ol-0-0-5349]). Apollon has been reported to serve a significant role in apoptosis resistance in a variety of cancers ([@b10-ol-0-0-5349],[@b19-ol-0-0-5349]--[@b23-ol-0-0-5349]), including breast cancers, colon cancers, gliomas, fibrosarcomas, osteosarcomas, lung cancers, cervical cancers and prostate cancers. However, a role for Apollon in renal cancer has rarely been reported. In the present study, Apollon was observed to also serve a role in apoptosis resistance in RC. These results are in agreement with those of Zhang *et al* ([@b24-ol-0-0-5349]). This process may facilitate further studies on RC.

Regarding the expression of IAPs in RC, previous studies revealed a significant overexpression of IAPs in cancer tissues and normal squamous epithelia, including cellular (c)IAP-1, cIAP-2, XIAP and survivin. However, the expression of these proteins was an early event in renal cancer, and did not correlate with the histological type of cancer or stage of the tumors ([@b25-ol-0-0-5349]--[@b27-ol-0-0-5349]). The potential roles of IAP family proteins in the homeostasis of normal tissues as well as in the pathogenesis of RC are still unknown, since studies on Apollon and RC are limited. In the present study, the differences in Apollon expression were compared in a variety of malignant renal tissues and adjacent non-cancerous tissues and benign renal tissues. Immunohistochemical staining revealed a markedly high frequency of Apollon expression in the majority of cancer cells. By contrast, in normal mucosa, the presence of positive cells was partial, and in certain cases, the signals were negative ([Fig. 1](#f1-ol-0-0-5349){ref-type="fig"}). Thus, differences in the positive cell ratio would result in differences in intensity of mRNA expression for Apollon, indicating that Apollon could have a significant role in renal cancer.

According to our immunohistochemistry data, Apollon protein was detected in the majority of cancer samples (42 of 50, 84%). The protein was located in the cytoplasm, which confirmed a previous study that reported that Apollon localized to the Golgi compartment and the vesicular system ([@b28-ol-0-0-5349]). The expression of Apollon was observed in numerous cases of normal squamous epithelial tissue, mainly in the basal layer ([@b28-ol-0-0-5349]). The expression of Apollon is ubiquitous in fetal tissues, but becomes restricted during development, and appears to be negligible in the majority of terminally differentiated adult tissues, which confirms its role in caryomitosis ([@b29-ol-0-0-5349]). From the clinical data, the present study noticed that the expression of Apollon was not associated with age, gender, tumor size or tumor differentiation, but exhibited a strong association with TNM-stage, T-staging and nodal involvement. These results indicated that high expression of Apollon leads to increased malignant biological characteristics, regardless of the degree of tumor differentiation, which is inconsistent with previous studies ([@b29-ol-0-0-5349]--[@b33-ol-0-0-5349]) reporting that Apollon expression indicates poor differentiation. By contrast, similar results to the ones reported in the present study were reported by Low *et al* ([@b23-ol-0-0-5349]), who studied the association between prostate cancer and Apollon. The results of that study indicated that increased expression of Apollon was a late event in prostate cancer and did not correlate with Gleason grade ([@b23-ol-0-0-5349]). Our data suggested that Apollon is functionally an indicator of metastasis or prognosis in renal cancer.

The increase in Apollon expression in renal cancer suggests an important role for this protein in the development and progression of the disease. In view of the pro-survival function of Apollon in RC cells and other systems ([@b12-ol-0-0-5349]--[@b14-ol-0-0-5349],[@b20-ol-0-0-5349]), a cytoprotective advantage to RC cells is expected to be provided by elevated expression of Apollon, thus promoting RC development and progression. Numerous previous studies have demonstrated that the expression level of Apollon was significantly associated with patients\' reaction to therapy, recurrence, OS, disease-free survival (DFS) and prognosis ([@b29-ol-0-0-5349]--[@b33-ol-0-0-5349]). A previous multivariate analysis revealed that Apollon was an independent prognostic factor for OS and DFS in human epithelial ovarian cancer ([@b29-ol-0-0-5349]), which is in agreement with our results. In addition, various *in vitro* studies have demonstrated that Apollon overexpression indicates a stronger resistance to chemotherapy, since silencing its expression can sensitize cancer cells to chemotherapy, which can be interpreted by the cytoprotective advantage of Apollon and the chemotherapeutic mechanism ([@b20-ol-0-0-5349],[@b21-ol-0-0-5349],[@b30-ol-0-0-5349]--[@b32-ol-0-0-5349]). However, the role of Apollon in renal cancer remains uncertain. The present study demonstrated that Apollon may be a therapeutic target and a potential predictor of prognosis in RC. Future studies are required to expand the therapeutic arsenal in the fight against renal cancer and to improve the quality of life of RC patients.

In conclusion, the present study indicates for the first time that Apollon expression is associated with the biological characteristics of renal cancer, and it is potentially a valuable predictor and novel target for renal cancers. Although the mechanisms of Apollon function in tumorigenesis and metastasis are still unclear, the present study provides evidence for further studies *in vitro* and *in vivo* to clarify the regulatory mechanisms of IAP expression in renal cancer in association with the apoptotic signaling pathways.

![Cytoplasmic Apollon expression was detected in RC tissues with different tumor differentiation degree: (A) Well-differentiated, (B) moderately differentiated and (C) poorly differentiated. (D) No expression of Apollon was detected in the cytoplasm of carcinoma cells in RC tissues, whereas rare cytoplasmic Apollon expression was detected in normal epithelium. (E) Apollon-positive tissues. Apollon expression was mainly observed in clear cells or underlying basal cells. (F) Apollon expression was negative in normal epithelium. Original magnification, ×200. RC, renal carcinoma.](ol-12-06-5129-g00){#f1-ol-0-0-5349}

![(A) Relative fold-change in Apollon mRNA expression in all RC specimens and adjacent non-cancerous tissues. Normal tissue was set as 1. The difference in Apollon mRNA expression between the three groups is significant. \*\*\*P\<0.001, comparison between the RC group and the adjacent group; ^\#^P=0.436, comparison between the adjacent group and the normal group. (B) Representative western blot analysis of Apollon protein expression in RC, adjacent non-cancerous tissue and normal tissue. \*\*\*P\<0.05, comparison between the RC group and the adjacent group; ^\#^P=0.706, comparison between the adjacent group and the normal group. Apollon expression in cancer is relatively high (P\<0.05). RC, renal carcinoma; mRNA, messenger RNA.](ol-12-06-5129-g01){#f2-ol-0-0-5349}

![Prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. The overall survival of patients with high Apollon expression was significantly shorter than that of patients with low Apollon expression.](ol-12-06-5129-g02){#f3-ol-0-0-5349}

###### 

Expression of Apollon in tumor, adjacent and normal epithelial tissues.

  Apollon expression   Cancer tissue   Adjacent tissue   Normal tissue
  -------------------- --------------- ----------------- ---------------
  Total, N                 50              42                30
  −                          8             28                20
  \+                         6               6                 7
  ++                         8               6                 3
  +++                      28                2                 0
  P-value              0.002           0.012             0.010

###### 

Associations between Apollon expression and clinicopathological characteristics of renal cancer patients.

                                                  Apollon         
  ----------------------------------------- ----- --------- ----- -------
  Gender                                                          0.201
    Male                                    48    26        22    
    Female                                    2     2         0   
  Age, years                                                      0.212
    ≥55                                     34    17        17    
    \<55                                    16    11          5   
  Alcohol consumption history (≥10 years)                         0.976
    Yes                                     41    23        18    
    No                                        9     5         4   
  Tumor size, cm                                                  0.749
    ≥4                                      26    14        12    
    \<4                                     24    14        10    
  Histological grade                                              0.156
    Well                                    16      6       10    
    Moderate                                26    16        10    
    Poor                                      8     6         2   
  T-stage                                                         0.006
    T1                                      11      3         8   
    T2                                      16      6       10    
    T3                                      18    15          3   
    T4                                        5     4         1   
  N-stage                                                         0.007
    N0                                      17      5       12    
    N1+N2+N3                                37    23        10    
  TNM-stage                                                       0.035
    I                                         4     2         2   
    II                                      20      7       13    
    III                                     26    19          7   

TNM, tumor-node-metastasis.

###### 

Cox proportional hazards regression model was used in univariate analysis.

  Characteristics             Hazard ratio (95% CI)   P-value
  --------------------------- ----------------------- ---------
  T-stage                     1.040                   0.883
  (T1 vs. T2 vs. T3 vs. T4)   (0.612--1.768)          
  TNM-stage                   2.458                   0.011
  (III vs. I and II)          (1.229--4.917)          
  Tumor size                  1.106                   0.663
  (≥4 cm vs. \<4 cm)          (0.702--1.744)          
  Apollon expression          0.855                   0.005
  (positive vs. negative)     (0.758--0.953)          

TNM, tumor-node-metastasis; CI, confidence interval.

[^1]: Contributed equally
